The escalating prevalence of liver and gallbladder disorders is a major driver for the growth of the market. Conditions like primary biliary cirrhosis, non-alcoholic fatty liver disease (NAFLD), gallstones, cystic fibrosis of liver, and others are increasingly diagnosed worldwide. For instance, according to the article published in Journal of Cystic Fibrosis, in 2022, around 162,428 people are estimated to be living with CF all over the globe. Ursodeoxycholic acid (UDCA) has great potential as an effective cystic fibrosis therapeutics.
Also, UDCA is undergoing extensive research for potential applications in addressing non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). For instance, in primary biliary cirrhosis, UDCA has been established as a standard treatment that can significantly slow disease progression. Additionally, UDCA is employed as a non-surgical option for certain gallstone types, as it aids in dissolving them. Thus, the continuous increase in the prevalence of liver and gallbladder disorders necessitates effective treatments, which in turn propels the demand for UDCA API-containing medications.